Clinical Trials
10 trialsNCT06724237 2026-05-15
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06561048 2026-04-08
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT03703375 2024-07-08
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Celgene
Phase 3 Active not recruiting
NCT05075460 2024-04-09
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
Peking Union Medical College Hospital
Phase 3 Unknown
NCT05466318 2022-07-25
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Phase 3 Unknown
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed
NCT01420679 2021-11-19
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT03349333 2019-10-01
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT00646854 2019-03-01
ACT-1
University of Aarhus
Phase 3 Completed
NCT00725231 2012-05-07
A-CHOP-14
University of Göttingen
Phase 3 Unknown